Move to topTop

New Delhi, July 30, 2024: Terumo India, the Indian arm of Japan-based Terumo Corporation (TSE: 4543), a global leader in medical technology, has been honoured with two recognitions for its health and wellbeing initiatives.

Terumo India was awarded the Best Health & Wellbeing Program of the Year at Synnex Group’s India HR Summit & Awards 2024 and received recognition for Excellence in Health and Wellness Initiatives at UBS Forums 17th Edition Future of L&D Summit and Awards 2024.

These recognitions are a testament to Terumo India's commitment to the health, safety, and well-being of its associates and their families. The company's global ethos, "Your health, your happiness, our priority," is embedded in all initiatives, ensuring a continued culture of well-being.

Some key initiatives include:

•    Flagship Wellbeing program - #CommitToBeFit: Focusing on comprehensive wellbeing solutions, including mental health, yoga, nutrition, fitness, family care, and preventive care
•    Fitness Challenges: Promoting the spirit of collective well-being and healthy habit formation through organisation-wide challenges such as the 21-Day Power Up Challenge, Plank Perseverance, and Surya Salutation challenges, achieving approximately 87% participation
•    Terumo Cares: Provides counselling for associates and their families
•    Doc on Call: Offers on-demand medical consultation
•    Hybrid Workplace Model embedding Future of Work: Combining remote and office work, promoting flexibility, trust, and work-life balance

Speaking on the initiatives, Ritu Anand, Senior Director - Human Resources, Administration and Corporate Communications, said: “At Terumo India, our commitment to associate well-being stands as the cornerstone of our organisational ethos. Witnessing the high-level engagement of our associates in our wellness initiatives fills me with immense pride. Achieving a 7.7 million energy score through fitness activities and actively participating in Mental Health Matters Day highlight the significant positive impact these programs have on our team. We continue to nurture an environment where each associate thrives.”

She further added, “We are truly committed to our philosophy of Powered by People. These awards belong to all our associates who initiated it, to the ones who participated in it, and to those who carry the culture forward. This recognition reaffirms our commitment, and I am extremely proud of the whole Terumo India team for making it possible.”

Terumo India has been recognised as a Great Place to Work® in 2024, 2022 and 2021. It is ranked among one of the Top 15 Companies as India's Best Workplaces™ in Pharmaceuticals, Healthcare and Biotech 2022, and is also ranked 77th among the Top 100 Companies in India's Great Mid-Size Workplaces™ listing.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.